Table 1 Patient Characteristics
From: Clinical significance of serum CA125 in diffuse malignant mesothelioma
Parameters | No. | (%) |
|---|---|---|
Total | 41 | 100 |
Sex ratio (M:F) | 28:13 | |
Median age, years (range) | 53 (24–80) | |
≤60 years | 28 | 68.3 |
>60 years | 13 | 31.7 |
Primary tumor location | ||
Pleura | 23 | 56.1 |
Peritoneum | 18 | 43.9 |
Histological subtype | ||
Epithelial | 14 | 34.2 |
Sarcomatoid | 1 | 2.4 |
Unspecified | 26 | 63.4 |
Stage of disease | ||
III | 10 | 24.4 |
IV | 31 | 75.6 |
Performance status (ECOG) | ||
0–1 | 33 | 80.5 |
2 | 8 | 19.5 |
Surgery | ||
Cytoreductive surgery | 11 | 26.8 |
non-cytoreductive surgery | 30 | 73.2 |
Systemic chemotherapy | ||
Yes | 23 | 56.1 |
No | 18 | 43.9 |
Median cycles of systemic chemotherapy (range) | 4 (1–15) | |
Local chemotherapy | ||
Yes | 13 | 31.7 |
Intrapleural chemotherapy | 5 | 38.5 |
Intraperitoneal chemotherapy | 8 | 61.5 |
No | 28 | 68.3 |
Median cycles of local treatment (range) | 5 (3–7) | |
Baseline of serum CA125 (range) | 351.3 (8.96–2017) | |
≤35 U/ml | 10 | 24.4 |
>35 U/ml | 31 | 75.6 |